Q3 FY2026 · ended Sep 30, 2026 · Revenue $139.36M, +39.3% YoY · Filed Oct 29, 2026
Caredx, Inc. (CDNA) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $139.4 million and net income of $19.3 million. Free cash flow was $11.1 million. As of Sep 30, 2026 it held $250.5 million in cash and investments and $29.0 million in total debt.
Revenue
$139.36M
+39.3% vs year-ago quarter
Net income
$19.29M
+1051.8% vs year-ago quarter
Operating cash flow
$12.72M
-66.0% vs year-ago quarter
Free cash flow
$11.10M
-61.4% vs prior quarter
EPS
$0.35
+1066.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
52.54M
+2.2% vs year-ago quarter
Net cash
$221.48M
Q3 FY2026
Operating margin
23.4%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- CDNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1217234
- Former names
- XDx, Inc. (until Nov 15, 2011); EXPRESSION DIAGNOSTICS INC (until Dec 14, 2005)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $139.4M | $131.9M | $117.7M | $108.4M | $100.1M |
| Operating income | $8.1M | $113.2M | $1.2M | -$6.0M | -$246,000 |
| Net income | $19.3M | $110.6M | $2.8M | -$4.1M | $1.7M |
| Diluted EPS | $0.35 | $2.07 | $0.05 | -$0.08 | $0.03 |
| Operating cash flow | $12.7M | $30.6M | $4.3M | $21.4M | $37.4M |
| Free cash flow | $11.1M | $28.7M | $514,000 | — | — |
| Total assets | $641.5M | $533.0M | $411.1M | $413.2M | $432.3M |
| Total liabilities | $174.0M | $107.4M | $97.5M | $110.1M | $121.2M |
| Stockholders' equity | $467.5M | $425.6M | $313.5M | $303.1M | $311.1M |
| Cash and investments | $250.5M | $373.6M | $198.1M | $201.4M | $194.2M |
| Total debt | $29.0M | $19.2M | $24.5M | $26.2M | $27.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
Sep 16, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
Jul 7, 2026 | Jun 30, 2026 |
All 1000 Caredx, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.